Merck Animal Health to Acquire Harrisvaccines Acquisition Expands and Complements Merck Animal Health’s Strong Vaccine Portfolio
MADISON, N.J., November 12, 2015 – Merck Animal Health (known as MSD Animal Health outside the United States and Canada) and Harrisvaccines, Inc., today announced the companies have entered into an agreement under which Merck Animal Health will acquire Harrisvaccines, a privately-held company that develops, manufactures and sells vaccines for food production and companion animals.
“As a leader in biologics, Merck Animal Health has built a robust portfolio of vaccines across all animal species,” stated Rick DeLuca, president, Merck Animal Health. “Combining Harrisvaccines’ R&D and portfolio of products with our strong capabilities and global reach will enable us to address even more devastating diseases that are impacting production animals and reinforce our commitment to the science of healthier animals.”
Harrisvaccines offers innovative technology and an important portfolio of vaccines, with a focus on production animals, an increasingly important segment as consumer demand for protein continues to grow worldwide. The company has a unique RNA Particle technology which represents a breakthrough in vaccine development. It also has a highly versatile production platform able to target a wide range of viruses and bacteria. Pathogens are collected from a farm and specific genes are sequenced and inserted into RNA particles, making safe, potent vaccines able to provide herd-specific protection.
This pioneering system is rapidly adaptable to new disease challenges and was instrumental in producing the first conditionally licensed vaccine to help control Porcine Epidemic Diarrhea Virus (PEDv), a deadly virus that has killed more than eight million piglets since suddenly emerging in the U.S. in 2013. In September 2015, Harrisvaccines received a conditional approval for a Eurasian H5 subtype avian influenza vaccine and was subsequently awarded a contract by the United States Department of Agriculture’s Animal and Plant Health Inspection Service (USDA/APHIS) to produce the vaccine.
“We are excited to join forces with Merck Animal Health,” said Dr. Hank Harris, founder and CEO of Harrisvaccines. “Their vaccine expertise, commercial reach and worldwide network of R&D and manufacturing sites, combined with our knowledge and novel technology, represents a tremendous opportunity to best serve producers and veterinarians as they protect the health of animals worldwide.”
The terms of the agreement were not disclosed. The companies expect the transaction to close in the fourth quarter of 2015.
About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn and Twitter at @MerckAH.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).